durvalumab
astrazeneca
['sclc', 'lcsm,(-blcsm)', 'nsclc', 'pacific', 'aura ']
important poster from regarding egfr nsclc. i ve always felt unsure about durva for these patients; good to see post-hoc pacific data (n=35) showing no pfs or os differences between io vs observation. await laura rct results. #asco22 #lcsm 
Thoracic oncologist @ CU | Interested in targeted therapies and novel biomarkers | Dabble with piano, film, and skiing on the side | Alum @Penn & @KeckMedUSC